+1 #(S1 (S (NP (NP (NN _PROT1_) (NN beta) (NN protein) (NN disruption)) (PP (IN of) (NP (ADJP (ADJP (JJ cholinergic)) (CC and) (NP (NN growth) (NN factor) (NN _PROT2_) (NN _PROT2_))) (NNS signals)))) (VP (MD could) (VP (VB underlie) (NP (NP (ADJP (ADJP (JJ cognitive)) (CC and) (ADJP (JJ neurodegerative))) (NNS aspects)) (PP (IN of) (NP (NN Alzheimer) (POS 's) (NN disease))))))))
+1 #(S1 (S (NP (DT The) (NN beta) (NN _PROT1_) (NN protein) (NNS fragments)) (VP (VBD had) (NP (NP (JJ diverse) (NNS effects)) (PP (IN on) (NP (NP (JJ phosphoinositide-specific) (NN _PROT2_) (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (NN PI-PLC)) (-RRB- -RRB-))))) (SBAR (IN as) (S (VP (VBN assayed) (PP (IN in) (NP (NN rat) (JJ cortical) (NNS membranes)))))))))
-1 #(S1 (S (SBAR (IN Once) (S (NP (NP (DT the) (ADJP (RB abnormally) (VBN phosphorylated)) (JJ abnormal) (NN _PROT1_) (NN _PROT1_) (NN isoform)) (NN agent)) (VP (VBZ is) (VP (VBN initiated))))) (, ,) (NP (NP (DT any) (NN stress) (NN event)) (VP (VBG ensuing) (PP (IN in) (NP (JJ adult) (NN life))))) (VP (VBZ induces) (NP (NP (DT a) (NN nerve) (NN growth) (JJ factor-mediated) (NN synthesis)) (PP (IN of) (NP (JJ normal) (JJ cellular) (NN _PROT2_) (NN _PROT2_) (NN isoform))) (SBAR (WHNP (WDT that)) (S (VP (VBZ aggregates) (PP (TO to) (NP (ADJP (RB abnormally) (VBN phosphorylated)) (JJ abnormal) (NN _PROT_) (NN _PROT_) (NN isoform))))))) (, ,) (S (ADVP (RB thereby)) (VP (VBG becoming) (ADJP (`` ') (JJ infected) ('' ') (JJ /transformed)) (PP (IN into) (NP (DT the) (JJ same)))))) (: ;) (S (ADJP (JJ due) (PP (TO to) (NP (NP (DT the) (JJ vicious) (NN circle)) (PP (IN of) (NP (NP (JJ positive) (NN feedback)) (VP (VBN invoked) (PP (IN by) (NP (NP (DT the) (NN blocking)) (PP (IN of) (NP (DT a) (NN _PROT_) (NN _PROT_) (NN _PROT_))))))))))))))
-1 #(S1 (S (SBAR (IN Once) (S (NP (NP (DT the) (ADJP (RB abnormally) (VBN phosphorylated)) (JJ abnormal) (NN _PROT1_) (NN _PROT1_) (NN isoform)) (NN agent)) (VP (VBZ is) (VP (VBN initiated))))) (, ,) (NP (NP (DT any) (NN stress) (NN event)) (VP (VBG ensuing) (PP (IN in) (NP (JJ adult) (NN life))))) (VP (VBZ induces) (NP (NP (DT a) (NN nerve) (NN growth) (JJ factor-mediated) (NN synthesis)) (PP (IN of) (NP (JJ normal) (JJ cellular) (NN _PROT_) (NN _PROT_) (NN isoform))) (SBAR (WHNP (WDT that)) (S (VP (VBZ aggregates) (PP (TO to) (NP (ADJP (RB abnormally) (VBN phosphorylated)) (JJ abnormal) (NN _PROT2_) (NN _PROT2_) (NN isoform))))))) (, ,) (S (ADVP (RB thereby)) (VP (VBG becoming) (ADJP (`` ') (JJ infected) ('' ') (JJ /transformed)) (PP (IN into) (NP (DT the) (JJ same)))))) (: ;) (S (ADJP (JJ due) (PP (TO to) (NP (NP (DT the) (JJ vicious) (NN circle)) (PP (IN of) (NP (NP (JJ positive) (NN feedback)) (VP (VBN invoked) (PP (IN by) (NP (NP (DT the) (NN blocking)) (PP (IN of) (NP (DT a) (NN _PROT_) (NN _PROT_) (NN _PROT_))))))))))))))
-1 #(S1 (S (SBAR (IN Once) (S (NP (NP (DT the) (ADJP (RB abnormally) (VBN phosphorylated)) (JJ abnormal) (NN _PROT1_) (NN _PROT1_) (NN isoform)) (NN agent)) (VP (VBZ is) (VP (VBN initiated))))) (, ,) (NP (NP (DT any) (NN stress) (NN event)) (VP (VBG ensuing) (PP (IN in) (NP (JJ adult) (NN life))))) (VP (VBZ induces) (NP (NP (DT a) (NN nerve) (NN growth) (JJ factor-mediated) (NN synthesis)) (PP (IN of) (NP (JJ normal) (JJ cellular) (NN _PROT_) (NN _PROT_) (NN isoform))) (SBAR (WHNP (WDT that)) (S (VP (VBZ aggregates) (PP (TO to) (NP (ADJP (RB abnormally) (VBN phosphorylated)) (JJ abnormal) (NN _PROT_) (NN _PROT_) (NN isoform))))))) (, ,) (S (ADVP (RB thereby)) (VP (VBG becoming) (ADJP (`` ') (JJ infected) ('' ') (JJ /transformed)) (PP (IN into) (NP (DT the) (JJ same)))))) (: ;) (S (ADJP (JJ due) (PP (TO to) (NP (NP (DT the) (JJ vicious) (NN circle)) (PP (IN of) (NP (NP (JJ positive) (NN feedback)) (VP (VBN invoked) (PP (IN by) (NP (NP (DT the) (NN blocking)) (PP (IN of) (NP (DT a) (NN _PROT2_) (NN _PROT2_) (NN _PROT_))))))))))))))
-1 #(S1 (S (SBAR (IN Once) (S (NP (NP (DT the) (ADJP (RB abnormally) (VBN phosphorylated)) (JJ abnormal) (NN _PROT1_) (NN _PROT1_) (NN isoform)) (NN agent)) (VP (VBZ is) (VP (VBN initiated))))) (, ,) (NP (NP (DT any) (NN stress) (NN event)) (VP (VBG ensuing) (PP (IN in) (NP (JJ adult) (NN life))))) (VP (VBZ induces) (NP (NP (DT a) (NN nerve) (NN growth) (JJ factor-mediated) (NN synthesis)) (PP (IN of) (NP (JJ normal) (JJ cellular) (NN _PROT_) (NN _PROT_) (NN isoform))) (SBAR (WHNP (WDT that)) (S (VP (VBZ aggregates) (PP (TO to) (NP (ADJP (RB abnormally) (VBN phosphorylated)) (JJ abnormal) (NN _PROT_) (NN _PROT_) (NN isoform))))))) (, ,) (S (ADVP (RB thereby)) (VP (VBG becoming) (ADJP (`` ') (JJ infected) ('' ') (JJ /transformed)) (PP (IN into) (NP (DT the) (JJ same)))))) (: ;) (S (ADJP (JJ due) (PP (TO to) (NP (NP (DT the) (JJ vicious) (NN circle)) (PP (IN of) (NP (NP (JJ positive) (NN feedback)) (VP (VBN invoked) (PP (IN by) (NP (NP (DT the) (NN blocking)) (PP (IN of) (NP (DT a) (NN _PROT_) (NN _PROT_) (NN _PROT2_))))))))))))))
-1 #(S1 (S (SBAR (IN Once) (S (NP (NP (DT the) (ADJP (RB abnormally) (VBN phosphorylated)) (JJ abnormal) (NN _PROT_) (NN _PROT_) (NN isoform)) (NN agent)) (VP (VBZ is) (VP (VBN initiated))))) (, ,) (NP (NP (DT any) (NN stress) (NN event)) (VP (VBG ensuing) (PP (IN in) (NP (JJ adult) (NN life))))) (VP (VBZ induces) (NP (NP (DT a) (NN nerve) (NN growth) (JJ factor-mediated) (NN synthesis)) (PP (IN of) (NP (JJ normal) (JJ cellular) (NN _PROT1_) (NN _PROT1_) (NN isoform))) (SBAR (WHNP (WDT that)) (S (VP (VBZ aggregates) (PP (TO to) (NP (ADJP (RB abnormally) (VBN phosphorylated)) (JJ abnormal) (NN _PROT2_) (NN _PROT2_) (NN isoform))))))) (, ,) (S (ADVP (RB thereby)) (VP (VBG becoming) (ADJP (`` ') (JJ infected) ('' ') (JJ /transformed)) (PP (IN into) (NP (DT the) (JJ same)))))) (: ;) (S (ADJP (JJ due) (PP (TO to) (NP (NP (DT the) (JJ vicious) (NN circle)) (PP (IN of) (NP (NP (JJ positive) (NN feedback)) (VP (VBN invoked) (PP (IN by) (NP (NP (DT the) (NN blocking)) (PP (IN of) (NP (DT a) (NN _PROT_) (NN _PROT_) (NN _PROT_))))))))))))))
-1 #(S1 (S (SBAR (IN Once) (S (NP (NP (DT the) (ADJP (RB abnormally) (VBN phosphorylated)) (JJ abnormal) (NN _PROT_) (NN _PROT_) (NN isoform)) (NN agent)) (VP (VBZ is) (VP (VBN initiated))))) (, ,) (NP (NP (DT any) (NN stress) (NN event)) (VP (VBG ensuing) (PP (IN in) (NP (JJ adult) (NN life))))) (VP (VBZ induces) (NP (NP (DT a) (NN nerve) (NN growth) (JJ factor-mediated) (NN synthesis)) (PP (IN of) (NP (JJ normal) (JJ cellular) (NN _PROT1_) (NN _PROT1_) (NN isoform))) (SBAR (WHNP (WDT that)) (S (VP (VBZ aggregates) (PP (TO to) (NP (ADJP (RB abnormally) (VBN phosphorylated)) (JJ abnormal) (NN _PROT_) (NN _PROT_) (NN isoform))))))) (, ,) (S (ADVP (RB thereby)) (VP (VBG becoming) (ADJP (`` ') (JJ infected) ('' ') (JJ /transformed)) (PP (IN into) (NP (DT the) (JJ same)))))) (: ;) (S (ADJP (JJ due) (PP (TO to) (NP (NP (DT the) (JJ vicious) (NN circle)) (PP (IN of) (NP (NP (JJ positive) (NN feedback)) (VP (VBN invoked) (PP (IN by) (NP (NP (DT the) (NN blocking)) (PP (IN of) (NP (DT a) (NN _PROT2_) (NN _PROT2_) (NN _PROT_))))))))))))))
-1 #(S1 (S (SBAR (IN Once) (S (NP (NP (DT the) (ADJP (RB abnormally) (VBN phosphorylated)) (JJ abnormal) (NN _PROT_) (NN _PROT_) (NN isoform)) (NN agent)) (VP (VBZ is) (VP (VBN initiated))))) (, ,) (NP (NP (DT any) (NN stress) (NN event)) (VP (VBG ensuing) (PP (IN in) (NP (JJ adult) (NN life))))) (VP (VBZ induces) (NP (NP (DT a) (NN nerve) (NN growth) (JJ factor-mediated) (NN synthesis)) (PP (IN of) (NP (JJ normal) (JJ cellular) (NN _PROT1_) (NN _PROT1_) (NN isoform))) (SBAR (WHNP (WDT that)) (S (VP (VBZ aggregates) (PP (TO to) (NP (ADJP (RB abnormally) (VBN phosphorylated)) (JJ abnormal) (NN _PROT_) (NN _PROT_) (NN isoform))))))) (, ,) (S (ADVP (RB thereby)) (VP (VBG becoming) (ADJP (`` ') (JJ infected) ('' ') (JJ /transformed)) (PP (IN into) (NP (DT the) (JJ same)))))) (: ;) (S (ADJP (JJ due) (PP (TO to) (NP (NP (DT the) (JJ vicious) (NN circle)) (PP (IN of) (NP (NP (JJ positive) (NN feedback)) (VP (VBN invoked) (PP (IN by) (NP (NP (DT the) (NN blocking)) (PP (IN of) (NP (DT a) (NN _PROT_) (NN _PROT_) (NN _PROT2_))))))))))))))
-1 #(S1 (S (SBAR (IN Once) (S (NP (NP (DT the) (ADJP (RB abnormally) (VBN phosphorylated)) (JJ abnormal) (NN _PROT_) (NN _PROT_) (NN isoform)) (NN agent)) (VP (VBZ is) (VP (VBN initiated))))) (, ,) (NP (NP (DT any) (NN stress) (NN event)) (VP (VBG ensuing) (PP (IN in) (NP (JJ adult) (NN life))))) (VP (VBZ induces) (NP (NP (DT a) (NN nerve) (NN growth) (JJ factor-mediated) (NN synthesis)) (PP (IN of) (NP (JJ normal) (JJ cellular) (NN _PROT_) (NN _PROT_) (NN isoform))) (SBAR (WHNP (WDT that)) (S (VP (VBZ aggregates) (PP (TO to) (NP (ADJP (RB abnormally) (VBN phosphorylated)) (JJ abnormal) (NN _PROT1_) (NN _PROT1_) (NN isoform))))))) (, ,) (S (ADVP (RB thereby)) (VP (VBG becoming) (ADJP (`` ') (JJ infected) ('' ') (JJ /transformed)) (PP (IN into) (NP (DT the) (JJ same)))))) (: ;) (S (ADJP (JJ due) (PP (TO to) (NP (NP (DT the) (JJ vicious) (NN circle)) (PP (IN of) (NP (NP (JJ positive) (NN feedback)) (VP (VBN invoked) (PP (IN by) (NP (NP (DT the) (NN blocking)) (PP (IN of) (NP (DT a) (NN _PROT2_) (NN _PROT2_) (NN _PROT_))))))))))))))
-1 #(S1 (S (SBAR (IN Once) (S (NP (NP (DT the) (ADJP (RB abnormally) (VBN phosphorylated)) (JJ abnormal) (NN _PROT_) (NN _PROT_) (NN isoform)) (NN agent)) (VP (VBZ is) (VP (VBN initiated))))) (, ,) (NP (NP (DT any) (NN stress) (NN event)) (VP (VBG ensuing) (PP (IN in) (NP (JJ adult) (NN life))))) (VP (VBZ induces) (NP (NP (DT a) (NN nerve) (NN growth) (JJ factor-mediated) (NN synthesis)) (PP (IN of) (NP (JJ normal) (JJ cellular) (NN _PROT_) (NN _PROT_) (NN isoform))) (SBAR (WHNP (WDT that)) (S (VP (VBZ aggregates) (PP (TO to) (NP (ADJP (RB abnormally) (VBN phosphorylated)) (JJ abnormal) (NN _PROT1_) (NN _PROT1_) (NN isoform))))))) (, ,) (S (ADVP (RB thereby)) (VP (VBG becoming) (ADJP (`` ') (JJ infected) ('' ') (JJ /transformed)) (PP (IN into) (NP (DT the) (JJ same)))))) (: ;) (S (ADJP (JJ due) (PP (TO to) (NP (NP (DT the) (JJ vicious) (NN circle)) (PP (IN of) (NP (NP (JJ positive) (NN feedback)) (VP (VBN invoked) (PP (IN by) (NP (NP (DT the) (NN blocking)) (PP (IN of) (NP (DT a) (NN _PROT_) (NN _PROT_) (NN _PROT2_))))))))))))))
+1 #(S1 (S (SBAR (IN Once) (S (NP (NP (DT the) (ADJP (RB abnormally) (VBN phosphorylated)) (JJ abnormal) (NN _PROT_) (NN _PROT_) (NN isoform)) (NN agent)) (VP (VBZ is) (VP (VBN initiated))))) (, ,) (NP (NP (DT any) (NN stress) (NN event)) (VP (VBG ensuing) (PP (IN in) (NP (JJ adult) (NN life))))) (VP (VBZ induces) (NP (NP (DT a) (NN nerve) (NN growth) (JJ factor-mediated) (NN synthesis)) (PP (IN of) (NP (JJ normal) (JJ cellular) (NN _PROT_) (NN _PROT_) (NN isoform))) (SBAR (WHNP (WDT that)) (S (VP (VBZ aggregates) (PP (TO to) (NP (ADJP (RB abnormally) (VBN phosphorylated)) (JJ abnormal) (NN _PROT_) (NN _PROT_) (NN isoform))))))) (, ,) (S (ADVP (RB thereby)) (VP (VBG becoming) (ADJP (`` ') (JJ infected) ('' ') (JJ /transformed)) (PP (IN into) (NP (DT the) (JJ same)))))) (: ;) (S (ADJP (JJ due) (PP (TO to) (NP (NP (DT the) (JJ vicious) (NN circle)) (PP (IN of) (NP (NP (JJ positive) (NN feedback)) (VP (VBN invoked) (PP (IN by) (NP (NP (DT the) (NN blocking)) (PP (IN of) (NP (DT a) (NN _PROT1_) (NN _PROT1_) (NN _PROT2_))))))))))))))
-1 #(S1 (S (NP (NP (DT The) (NNS responses)) (PP (IN of) (NP (NP (NP (NN serum) (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN OT)) (-RRB- -RRB-))) (CC and) (NP (NP (NN vasopressin)) (PRN (-LRB- -LRB-) (NP (NN AVP)) (-RRB- -RRB-))))) (PP (TO to) (NP (NP (NP (DT the) (JJ serotonergic) (NN HT1A) (NN agonist) (NN buspirone)) (PRN (-LRB- -LRB-) (NP (CD 15) (NN mg) (NN p.o.)) (-RRB- -RRB-))) (CC or) (NP (NP (DT the) (NN HTD1) (NN agonist) (NN sumatriptan)) (PRN (-LRB- -LRB-) (NP (NP (CD 6) (NN mg)) (VP (VBN injected) (ADVP (RB subcutaneously)))) (-RRB- -RRB-)))))) (VP (VBD were) (VP (VBN evaluated) (PP (IN in) (NP (CD 7) (JJ normal) (NNS men))) (PP (CC either) (PP (IN in) (NP (JJ basal) (NNS conditions))) (CC or) (PP (IN during) (NP (NP (DT an) (NN _PROT2_) (PRN (-LRB- -LRB-) (NP (NP (NN 0.15) (NN iu/kg)) (PP (IN as) (NP (DT an) (NN i.v.) (NN bolus)))) (-RRB- -RRB-)) (NN tolerance) (NN test)) (PRN (-LRB- -LRB-) (NP (NN ITT)) (-RRB- -RRB-)))))))))
+1 #(S1 (S (NP (NP (NN Stimulation)) (PP (IN of) (NP (JJ 5HT-1D) (NNS receptors))) (PP (IN with) (NP (NN sumatriptan)))) (VP (VBD was) (ADJP (JJ unable) (PP (TO to) (NP (NP (NP (NN change)) (CC neither) (NP (NN AVP))) (CC nor) (NP (NP (NN _PROT1_) (NN response)) (PP (TO to) (NP (JJ _PROT2_) (NN hypoglycemia))))))))))
+1 #(S1 (S (NP (NP (NP (NN Induction)) (PP (IN by) (NP (NP (NN _PROT1_)) (PP (IN of) (NP (NN _PROT2_) (NN _PROT2_)))))) (CC and) (NP (NP (NNS enzymes)) (PP (IN of) (NP (JJ fatty) (NN acid) (NN oxidation)))))))
+1 #(S1 (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP (NN _PROT1_)) (VP (VBZ alters) (PP (IN in) (NP (JJ pancreatic) (NNS islets))) (NP (NP (DT the) (NN mRNA)) (PP (IN of) (NP (NP (DT the) (NNS genes)) (VP (VBG encoding) (NP (NP (NP (NNS enzymes)) (PP (IN of) (NP (JJ free) (JJ fatty) (NN acid) (NN metabolism)))) (CC and) (NP (NP (NN _PROT2_) (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (NN UCP-2)) (-RRB- -RRB-))))))))))))))
+1 #(S1 (S (NP (NN _PROT1_) (NN overexpression)) (VP (VBD increased) (NP (NN _PROT2_) (NN mRNA)) (PP (IN by) (NP (JJR more) (IN than) (RB 10-fold))) (PP (IN in) (NP (NP (NP (NN epididymal)) (, ,) (NP (NN retroperitoneal)) (, ,) (CC and) (NP (NP (JJ subcutaneous) (JJ fat) (NN tissue)) (PP (IN of) (NP (JJ normal))))) (, ,) (CONJP (CC but) (RB not)) (PP (IN of) (NP (JJ leptin-receptor-defective) (JJ obese) (NNS rats))))))))
+1 #(S1 (S (PP (IN By) (S (ADVP (RB directly)) (VP (VBG regulating) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (NNS enzymes)) (PP (PP (IN of) (NP (JJ free) (JJ fatty) (NN acid) (NN metabolism))) (CC and) (PP (IN of) (NP (NN _PROT1_)))))))))) (, ,) (NP (NN _PROT2_)) (VP (VBZ controls) (NP (NP (JJ intracellular) (NN triglyceride) (NN content)) (PP (IN of) (NP (NP (JJ certain) (NNS nonadipocytes)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NNS adipocytes))))))))
+1 #(S1 (S (NP (NP (DT The) (NN activity)) (PP (IN of) (NP (NP (DT the) (NNS MAPKs)) (, ,) (VP (VBN induced) (PP (IN by) (NP (NP (NN _PROT1_)) (CC or) (NP (NN PMA)))))))) (VP (VBD was) (VP (VBN inhibited) (PP (PP (IN by) (NP (NP (NN downregulation)) (PP (IN of) (NP (NP (NN _PROT2_) (NN _PROT2_) (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (NN PKC)) (-RRB- -RRB-)))))) (, ,) (PP (IN by) (NP (DT the) (NN tyrosine) (NN kinase) (NN inhibitor) (NN genistein))) (CC and) (PP (IN by) (NP (NP (NP (NP (NN MAPK) (NN kinase)) (PRN (-LRB- -LRB-) (NP (NN MEK)) (-RRB- -RRB-))) (NN inhibitor)) (, ,) (NP (NN PD98059)))))))))
+1 #(S1 (S (NP (PRP We)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN _PROT1_)) (VP (VBZ activates) (NP (DT the) (JJ 42/44kDa) (NNS MAPKs)) (PP (IN through) (NP (NP (DT a) (NN signal) (NN transduction) (NN pathway)) (SBAR (WHNP (WDT that)) (S (VP (VBZ involves) (NP (NP (NN stimulation)) (PP (IN of) (NP (NP (NN AVP-V1) (NN receptor)) (, ,) (NP (NN tyrosine) (NN kinase)) (, ,) (NP (NN _PROT2_)) (CC and) (NP (NN MEK))))))))))))))))
-1 #(S1 (S (ADVP (RB Similarly)) (, ,) (NP (NP (NN carbachol)) (, ,) (CONJP (CC but) (RB not)) (NP (NP (NN _PROT1_)) (CC or) (NP (NN DDAVP))) (, ,)) (VP (VBD induced) (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN in) (NP (NP (NP (JJ membrane-associated) (NN _PROT2_) (NN _PROT2_) (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (NN PKC)) (-RRB- -RRB-))) (NN enzyme) (NN activity)))))))
-1 #(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (PRP _PROT1_)) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN distribution)) (PP (IN of) (NP (DT any) (NN _PROT2_) (NN isoform)))))) (VP (VBD tested))))
+1 #(S1 (S (NP (NP (NN Treatment)) (PP (IN with) (NP (PRN (-LRB- -LRB-) (CC +) (-RRB- -RRB-)) (NN -trifluoro-ABA)))) (ADVP (RB strongly)) (VP (VBD inhibited) (NP (NP (DT the) (JJ _PROT1_) (JJ _PROT1_) (NN expression)) (PP (IN of) (NP (NP (NN _PROT2_) (NN I-1)) (VP (VBN encoded) (PP (IN by) (NP (NN RAmy1A)))))) (PP (IN in) (NP (NP (DT the) (JJ aleurone) (NNS layers)) (PP (IN of) (NP (NN embryoless) (NNS half-seeds)))))) (PP (IN at) (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (NP (NN transcription)) (, ,) (NP (NN protein) (NN synthesis)) (, ,) (CC and) (NP (NN enzyme) (NN activity)))))))))
+1 #(S1 (S (NP (JJ Chronic) (JJ central) (NN _PROT1_) (NN infusion)) (VP (VP (VBZ enhances) (NP (JJ insulin-stimulated) (NN glucose) (NN metabolism))) (CC and) (VP (VBZ favors) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NN _PROT2_) (NNS _PROT2_))))))))
+1 #(S1 (S (PP (IN In) (NP (JJ marked) (NN contrast))) (, ,) (NP (JJ intracerebroventricular) (NN _PROT1_) (NN administration)) (VP (VBD was) (VP (VBN accompanied) (PP (IN by) (NP (NP (DT the) (NN maintenance)) (PP (IN of) (NP (NP (JJ high) (NN _PROT2_)) (, ,) (NP (NN _PROT_)) (, ,) (CC and) (NP (NN _PROT_)) (NP (NN expression)))) (PP (IN in) (NP (PDT all) (DT these) (NNS tissues)))))))))
+1 #(S1 (S (PP (IN In) (NP (JJ marked) (NN contrast))) (, ,) (NP (JJ intracerebroventricular) (NN _PROT1_) (NN administration)) (VP (VBD was) (VP (VBN accompanied) (PP (IN by) (NP (NP (DT the) (NN maintenance)) (PP (IN of) (NP (NP (JJ high) (NN _PROT_)) (, ,) (NP (NN _PROT2_)) (, ,) (CC and) (NP (NN _PROT_)) (NP (NN expression)))) (PP (IN in) (NP (PDT all) (DT these) (NNS tissues)))))))))
+1 #(S1 (S (PP (IN In) (NP (JJ marked) (NN contrast))) (, ,) (NP (JJ intracerebroventricular) (NN _PROT1_) (NN administration)) (VP (VBD was) (VP (VBN accompanied) (PP (IN by) (NP (NP (DT the) (NN maintenance)) (PP (IN of) (NP (NP (JJ high) (NN _PROT_)) (, ,) (NP (NN _PROT_)) (, ,) (CC and) (NP (NN _PROT2_)) (NP (NN expression)))) (PP (IN in) (NP (PDT all) (DT these) (NNS tissues)))))))))
-1 #(S1 (S (PP (IN In) (NP (JJ marked) (NN contrast))) (, ,) (NP (JJ intracerebroventricular) (NN _PROT_) (NN administration)) (VP (VBD was) (VP (VBN accompanied) (PP (IN by) (NP (NP (DT the) (NN maintenance)) (PP (IN of) (NP (NP (JJ high) (NN _PROT1_)) (, ,) (NP (NN _PROT2_)) (, ,) (CC and) (NP (NN _PROT_)) (NP (NN expression)))) (PP (IN in) (NP (PDT all) (DT these) (NNS tissues)))))))))
-1 #(S1 (S (PP (IN In) (NP (JJ marked) (NN contrast))) (, ,) (NP (JJ intracerebroventricular) (NN _PROT_) (NN administration)) (VP (VBD was) (VP (VBN accompanied) (PP (IN by) (NP (NP (DT the) (NN maintenance)) (PP (IN of) (NP (NP (JJ high) (NN _PROT1_)) (, ,) (NP (NN _PROT_)) (, ,) (CC and) (NP (NN _PROT2_)) (NP (NN expression)))) (PP (IN in) (NP (PDT all) (DT these) (NNS tissues)))))))))
-1 #(S1 (S (PP (IN In) (NP (JJ marked) (NN contrast))) (, ,) (NP (JJ intracerebroventricular) (NN _PROT_) (NN administration)) (VP (VBD was) (VP (VBN accompanied) (PP (IN by) (NP (NP (DT the) (NN maintenance)) (PP (IN of) (NP (NP (JJ high) (NN _PROT_)) (, ,) (NP (NN _PROT1_)) (, ,) (CC and) (NP (NN _PROT2_)) (NP (NN expression)))) (PP (IN in) (NP (PDT all) (DT these) (NNS tissues)))))))))
+1 #(S1 (S (SBAR (IN While) (S (NP (NN _PROT1_)) (VP (VP (VBZ maintains)) (CC or) (VP (VBZ favors) (NP (NP (JJ energy-dissipating) (NNS mechanisms)) (PRN (-LRB- -LRB-) (NP (NP (NN _PROT2_)) (, ,) (NP (NN _PROT_)) (, ,) (CC and) (NP (NN _PROT_))) (-RRB- -RRB-))))))) (, ,) (S (NP (DT the) (JJ latter)) (VP (VBP are) (VP (ADVP (RB markedly)) (VBN depressed) (PP (IN in) (NP (JJ pair-fed) (NNS rats))))))))
+1 #(S1 (S (SBAR (IN While) (S (NP (NN _PROT1_)) (VP (VP (VBZ maintains)) (CC or) (VP (VBZ favors) (NP (NP (JJ energy-dissipating) (NNS mechanisms)) (PRN (-LRB- -LRB-) (NP (NP (NN _PROT_)) (, ,) (NP (NN _PROT2_)) (, ,) (CC and) (NP (NN _PROT_))) (-RRB- -RRB-))))))) (, ,) (S (NP (DT the) (JJ latter)) (VP (VBP are) (VP (ADVP (RB markedly)) (VBN depressed) (PP (IN in) (NP (JJ pair-fed) (NNS rats))))))))
+1 #(S1 (S (SBAR (IN While) (S (NP (NN _PROT1_)) (VP (VP (VBZ maintains)) (CC or) (VP (VBZ favors) (NP (NP (JJ energy-dissipating) (NNS mechanisms)) (PRN (-LRB- -LRB-) (NP (NP (NN _PROT_)) (, ,) (NP (NN _PROT_)) (, ,) (CC and) (NP (NN _PROT2_))) (-RRB- -RRB-))))))) (, ,) (S (NP (DT the) (JJ latter)) (VP (VBP are) (VP (ADVP (RB markedly)) (VBN depressed) (PP (IN in) (NP (JJ pair-fed) (NNS rats))))))))
-1 #(S1 (S (SBAR (IN While) (S (NP (NN _PROT_)) (VP (VP (VBZ maintains)) (CC or) (VP (VBZ favors) (NP (NP (JJ energy-dissipating) (NNS mechanisms)) (PRN (-LRB- -LRB-) (NP (NP (NN _PROT1_)) (, ,) (NP (NN _PROT2_)) (, ,) (CC and) (NP (NN _PROT_))) (-RRB- -RRB-))))))) (, ,) (S (NP (DT the) (JJ latter)) (VP (VBP are) (VP (ADVP (RB markedly)) (VBN depressed) (PP (IN in) (NP (JJ pair-fed) (NNS rats))))))))
-1 #(S1 (S (SBAR (IN While) (S (NP (NN _PROT_)) (VP (VP (VBZ maintains)) (CC or) (VP (VBZ favors) (NP (NP (JJ energy-dissipating) (NNS mechanisms)) (PRN (-LRB- -LRB-) (NP (NP (NN _PROT1_)) (, ,) (NP (NN _PROT_)) (, ,) (CC and) (NP (NN _PROT2_))) (-RRB- -RRB-))))))) (, ,) (S (NP (DT the) (JJ latter)) (VP (VBP are) (VP (ADVP (RB markedly)) (VBN depressed) (PP (IN in) (NP (JJ pair-fed) (NNS rats))))))))
-1 #(S1 (S (SBAR (IN While) (S (NP (NN _PROT_)) (VP (VP (VBZ maintains)) (CC or) (VP (VBZ favors) (NP (NP (JJ energy-dissipating) (NNS mechanisms)) (PRN (-LRB- -LRB-) (NP (NP (NN _PROT_)) (, ,) (NP (NN _PROT1_)) (, ,) (CC and) (NP (NN _PROT2_))) (-RRB- -RRB-))))))) (, ,) (S (NP (DT the) (JJ latter)) (VP (VBP are) (VP (ADVP (RB markedly)) (VBN depressed) (PP (IN in) (NP (JJ pair-fed) (NNS rats))))))))
+1 #(S1 (S (NP (NN Melatonin)) (VP (VBZ inhibits) (NP (NP (NN _PROT1_) (NN response)) (PP (PP (TO to) (NP (JJ _PROT2_) (NN hypoglycemia))) (, ,) (CC but) (PP (RB not) (TO to) (NP (NN angiotensin) (CD II)))) (PP (IN in) (NP (JJ normal) (NNS men)))))))
-1 #(S1 (S (SBAR (IN In) (S (NP (NN order)) (VP (TO to) (VP (VB establish) (SBAR (IN whether) (S (NP (NN melatonin)) (VP (VBZ alters) (NP (ADJP (ADJP (JJ basal)) (CC and/or) (ADJP (JJ stimulated))) (NN _PROT1_) (NN secretion))))))))) (, ,) (S (NP (CD 18) (JJ normal) (NNS men)) (VP (VBD were) (VP (VBN treated) (PRN (-LRB- -LRB-) (NP (NN p.o.)) (-RRB- -RRB-)) (PP (IN with) (NP (NP (NP (NP (NP (NP (ADJP (QP (CD 6) (CC or) (CD 12)) (NN mg)) (NN melatonin)) (CC or) (NP (NN placebo))) (PP (PP (IN in) (NP (NP (JJ basal) (NNS conditions)) (PRN (-LRB- -LRB-) (NP (NN N-6) (NNS subjects)) (-RRB- -RRB-)))) (CC or) (PP (RB concomitantly) (TO to) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NN _PROT2_))))))) (-LRB- -LRB-) (NP (CD O.15) (NN IU/kg) (NN body) (NN weight)) (PP (IN in) (NP (DT an) (NN i.v.) (NN bolus))) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (NN N-6) (NNS subjects)) (-RRB- -RRB-))) (CC or) (NP (NP (NN angiotensin) (CD II)) (PRN (-LRB- -LRB-) (NP (NP (NP (VBG increasing) (NNS doses)) (PP (IN of) (NP (QP (CD 4) (, ,) (CD 8) (CC and) (CD 16)) (NN ng/kg/min)))) (, ,) (PP (IN at) (NP (NP (NNS intervals)) (PP (IN of) (NP (CD 20) (NN min)))))) (-RRB- -RRB-))))))))))
+1 #(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (DT the) (NN _PROT1_) (NN response)) (PP (TO to) (NP (JJ _PROT2_) (NN hypoglycemia)))) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN reduced) (PP (IN by) (NP (NN melatonin) (NN treatment)))))))
+1 #(S1 (S (NP (NP (NN Effect)) (PP (IN of) (NP (JJ residual) (JJ endogenous) (NN _PROT1_) (NN secretion))) (PP (IN on) (NP (NP (DT the) (JJ abnormal) (NN _PROT2_) (NN response)) (PP (TO to) (NP (NN hypoglycaemia))) (PP (IN in) (NP (JJ _PROT_) (NNS diabetics))))))))
-1 #(S1 (S (NP (NP (NN Effect)) (PP (IN of) (NP (JJ residual) (JJ endogenous) (NN _PROT1_) (NN secretion))) (PP (IN on) (NP (NP (DT the) (JJ abnormal) (NN _PROT_) (NN response)) (PP (TO to) (NP (NN hypoglycaemia))) (PP (IN in) (NP (JJ _PROT2_) (NNS diabetics))))))))
-1 #(S1 (S (NP (NP (NN Effect)) (PP (IN of) (NP (JJ residual) (JJ endogenous) (NN _PROT_) (NN secretion))) (PP (IN on) (NP (NP (DT the) (JJ abnormal) (NN _PROT1_) (NN response)) (PP (TO to) (NP (NN hypoglycaemia))) (PP (IN in) (NP (JJ _PROT2_) (NNS diabetics))))))))
+1 #(S1 (S (SBAR (IN Since) (S (NP (JJ previous) (NNS studies)) (VP (VBD showed) (SBAR (IN that) (S (NP (NN AVP) (NN secretion)) (VP (VBZ is) (VP (VBN influenced) (PP (IN by) (NP (NP (DT the) (NN persistence)) (PP (IN of) (NP (JJ residual) (JJ endogenous) (NN _PROT1_) (NN secretion)))))))))))) (, ,) (S (NP (PRP we)) (VP (VBD wondered) (SBAR (IN whether) (S (NP (DT this) (NN factor)) (ADVP (RB also)) (VP (VBZ regulates) (NP (NN _PROT2_) (NN secretion)))))))))
+1 #(S1 (S (NP (NP (NN DESIGN)) (: :) (NP (JJ Case-control) (NN study)) (: :) (S (NP (NP (DT the) (JJ _PROT1_) (NN response)) (PP (TO to) (NP (JJ _PROT2_) (NN hypoglycaemia)))) (VP (VBD was) (VP (VBN measured) (PP (IN in) (NP (NP (ADJP (ADJP (JJ normal)) (CC and) (ADJP (JJ diabetic))) (NNS patients)) (PP (PP (IN with)) (CC or) (PP (IN without) (NP (JJ residual) (JJ endogenous) (NN _PROT_) (NN secretion))))))))))))
-1 #(S1 (S (NP (NP (NN DESIGN)) (: :) (NP (JJ Case-control) (NN study)) (: :) (S (NP (NP (DT the) (JJ _PROT1_) (NN response)) (PP (TO to) (NP (JJ _PROT_) (NN hypoglycaemia)))) (VP (VBD was) (VP (VBN measured) (PP (IN in) (NP (NP (ADJP (ADJP (JJ normal)) (CC and) (ADJP (JJ diabetic))) (NNS patients)) (PP (PP (IN with)) (CC or) (PP (IN without) (NP (JJ residual) (JJ endogenous) (NN _PROT2_) (NN secretion))))))))))))
-1 #(S1 (S (NP (NP (NN DESIGN)) (: :) (NP (JJ Case-control) (NN study)) (: :) (S (NP (NP (DT the) (JJ _PROT_) (NN response)) (PP (TO to) (NP (JJ _PROT1_) (NN hypoglycaemia)))) (VP (VBD was) (VP (VBN measured) (PP (IN in) (NP (NP (ADJP (ADJP (JJ normal)) (CC and) (ADJP (JJ diabetic))) (NNS patients)) (PP (PP (IN with)) (CC or) (PP (IN without) (NP (JJ residual) (JJ endogenous) (NN _PROT2_) (NN secretion))))))))))))
-1 #(S1 (S (NP (NP (NN Blood) (NNS samples)) (PP (IN for) (NP (NN _PROT1_) (NN assay)))) (VP (VBD were) (VP (VBN taken) (PP (ADVP (RB just)) (PP (IN before) (NP (NP (NP (DT the) (JJ rapid) (NN injection)) (PP (IN of) (NP (NN _PROT2_)))) (PRN (-LRB- -LRB-) (NP (NN time) (CD 0)) (-RRB- -RRB-)))) (CC and) (PP (IN at) (NP (NN time))) (NP (QP (CD 15) (, ,) (CD 30) (, ,) (CD 45) (CC and) (CD 60)) (NN min)))))))
+1 #(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (DT These) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (DT a) (JJ residual) (JJ endogenous) (NN _PROT1_) (NN secretion)) (VP (VBZ exerts) (NP (NP (DT a) (JJ partial) (JJ protective) (NN action)) (PP (IN against) (NP (NP (DT the) (JJ hypothalamic-pituitary) (NN disorder)) (VP (VBG affecting) (NP (NP (DT the) (JJ _PROT2_) (JJ secretory) (NN system)) (PP (IN in) (NP (NN IDDM))))))))))))))))
+1 #(S1 (S (NP (DT These) (NNS findings)) (VP (VBD led) (S (NP (PRP us)) (VP (TO to) (VP (VB conclude) (SBAR (IN that) (S (NP (NP (NN inositol) (NN trisphosphate)) (NN [corrected) (-RRB- -RSB-)) (VP (VBZ causes) (NP (NN Ca2+) (NN mobilization)) (PP (IN by) (NP (NP (JJ muscarinic) (NN activation)) (PP (IN of) (NP (NN _PROT1_))))) (, ,) (S (VP (VBG leading) (PP (TO to) (NP (NP (JJ intracellular) (NN translocation)) (PP (IN of) (NP (NN _PROT2_) (NNS granules))) (PP (TO to) (NP (NP (DT the) (JJ ready-releasable) (NN pool)) (PP (IN in) (NP (JJ pancreatic) (NNS beta-cells))))))) (PP (IN via) (NP (NP (JJ Ca2+/calmodulin-dependent) (NN phosphorylation)) (PP (IN of) (NP (NN myosin) (NN light) (NNS chains))))))))))))))))
+1 #(S1 (S (NP (NN DNase1) (NNS footprints)) (VP (VBP suggest) (NP (NP (DT the) (NN involvement)) (PP (IN of) (NP (NP (QP (IN at) (JJS least) (CD three)) (NNS types)) (PP (IN of) (NP (NN transcription) (NNS factors))))) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NN _PROT1_))) (PP (IN by) (NP (NN _PROT2_)))))))))
+1 #(S1 (S (NP (NP (DT The) (NN regulation)) (PP (IN of) (NP (NN _PROT1_) (NNS genes))) (PP (IN by) (NP (NN _PROT2_)))) (ADVP (RB therefore)) (VP (VBZ involves) (NP (NP (DT an) (NN interplay)) (PP (IN of) (NP (NP (QP (IN at) (JJS least) (CD three)) (JJ different) (NNS types)) (PP (IN of) (NP (NN transcription) (NN factor)))))))))
+1 #(S1 (S (NP (NP (NNS Analyses)) (PP (IN of) (NP (NP (NN hormone) (NN regulation)) (PP (IN of) (NP (NP (NN expression)) (PP (IN of) (NP (NP (NN mRNA)) (PP (IN for) (NP (DT the) (NN aleurone) (NN RNase)))))))))) (VP (VBD revealed) (SBAR (IN that) (S (, ,) (PP (IN like) (NP (NP (DT the) (NN pattern)) (PP (IN for) (NP (NN _PROT1_))))) (, ,) (S (NP (NN mRNA) (NNS levels)) (VP (VBD increased) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ _PROT2_) (NN _PROT2_))))))) (, ,) (CC and) (S (NP (PRP$ its) (NN antagonist) (JJ abscisic) (NN acid)) (VP (VBD prevented) (NP (DT this) (NN effect)))))))))
+1 #(S1 (S (NP (NP (JJ Quantitative) (NNS studies)) (PP (IN at) (NP (JJ early) (NNS times)))) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NP (NN cycloheximide) (NN treatment)) (PP (IN of) (NP (NN aleurone) (NNS layers)))) (VP (VBD increased) (NP (NN mRNA) (NNS levels)) (ADVP (RB 4-fold)) (, ,) (SBAR (IN whereas) (S (NP (NP (DT a) (NN combination)) (PP (IN of) (NP (NP (NN _PROT1_)) (CC plus) (NP (NN cycloheximide) (NN treatment))))) (VP (VBD was) (VP (VBN required) (S (VP (TO to) (VP (VB increase) (NP (NN _PROT2_) (NN mRNA) (NNS levels)) (PP (TO to) (NP (DT the) (JJ same) (NN extent))))))))))))))))
+1 #(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (NP (PRP we)) (VP (VBD found) (SBAR (IN that) (S (PP (IN at) (NP (VBG increasing) (NN _PROT1_) (NNS concentrations))) (, ,) (NP (NP (VBG increasing) (NNS numbers)) (PP (IN of) (NP (NP (NP (NN barley)) (PRN (-LRB- -LRB-) (NP (NN Hordeum) (NN vulgare)) (-RRB- -RRB-))) (NNS cells)))) (VP (VBD showed) (NP (NP (DT the) (VBN enhanced) (NP (NP (NN _PROT2_) (NN secretion)) (CC and) (NP (NN vacuolation))) (NN characteristic)) (PP (IN of) (NP (DT the) (JJ _PROT_) (NN response))))))))))
-1 #(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (NP (PRP we)) (VP (VBD found) (SBAR (IN that) (S (PP (IN at) (NP (VBG increasing) (NN _PROT1_) (NNS concentrations))) (, ,) (NP (NP (VBG increasing) (NNS numbers)) (PP (IN of) (NP (NP (NP (NN barley)) (PRN (-LRB- -LRB-) (NP (NN Hordeum) (NN vulgare)) (-RRB- -RRB-))) (NNS cells)))) (VP (VBD showed) (NP (NP (DT the) (VBN enhanced) (NP (NP (NN _PROT_) (NN secretion)) (CC and) (NP (NN vacuolation))) (NN characteristic)) (PP (IN of) (NP (DT the) (JJ _PROT2_) (NN response))))))))))
-1 #(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (NP (PRP we)) (VP (VBD found) (SBAR (IN that) (S (PP (IN at) (NP (VBG increasing) (NN _PROT_) (NNS concentrations))) (, ,) (NP (NP (VBG increasing) (NNS numbers)) (PP (IN of) (NP (NP (NP (NN barley)) (PRN (-LRB- -LRB-) (NP (NN Hordeum) (NN vulgare)) (-RRB- -RRB-))) (NNS cells)))) (VP (VBD showed) (NP (NP (DT the) (VBN enhanced) (NP (NP (NN _PROT1_) (NN secretion)) (CC and) (NP (NN vacuolation))) (NN characteristic)) (PP (IN of) (NP (DT the) (JJ _PROT2_) (NN response))))))))))
+1 #(S1 (S (NP (NN _PROT1_)) (VP (VBZ is) (NP (NP (DT a) (NN satiety) (NN factor)) (SBAR (WHNP (WDT which)) (S (VP (VBZ acts) (PP (IN within) (NP (DT the) (NN hypothalamus))) (S (VP (TO to) (VP (VB decrease) (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (NP (NP (JJ several) (NNS neuropeptides)) (VP (VBG stimulating) (NP (NN food) (NN intake)))) (PRN (-LRB- -LRB-) (PP (IN among) (NP (PRP them))) (, ,) (NP (NN _PROT2_) (NN _PROT2_) (CD [NPY)) (-RRB- -RSB-) (-RRB- -RRB-)))))))))))) (, ,) (SBAR (IN while) (S (VP (VBG increasing) (NP (NP (DT those)) (SBAR (WHNP (WDT that)) (S (VP (VBP inhibit) (NP (NN food) (NN intake))))))))))))
-1 #(S1 (S (SBAR (IN Although) (S (NP (DT the) (JJ above) (NNS data)) (VP (VBP are) (ADJP (JJ consistent) (PP (IN with) (NP (NP (DT a) (JJ direct) (NN ability)) (PP (IN of) (NP (NN _PROT1_))) (S (VP (TO to) (VP (VB promote) (NP (NN TRH) (NN biosynthesis)) (PP (IN through) (NP (NP (NNS actions)) (PP (IN on) (NP (NN TRH) (NNS neurons)))))))))))))) (, ,) (NP (NP (NN addition)) (PP (IN of) (NP (NN a-MSH)))) (VP (VBD produced) (NP (NP (DT a) (CD 3.5) (NN fold) (NN increase)) (PP (IN in) (NP (NP (NN TRH) (NN biosynthesis)) (CC and) (NP (NN release))))) (, ,) (SBAR (IN whereas) (S (NP (NN _PROT2_) (NN treatment)) (VP (VBD suppressed) (NP (NN ~3) (NN fold) (NN proTRH) (NN biosynthesis))))))))
-1 #(S1 (S (NP (DT These) (NNS findings)) (VP (VBP are) (ADJP (JJ consistent) (PP (IN with) (NP (NP (VBN increased) (NN _PROT1_) (NN signaling)) (PP (TO to) (NP (NP (DT the) (NP (NN _PROT2_)) (CC and) (NP (JJ POMC) (NNS neurons))) (PP (IN in) (NP (DT the) (NN ARC)))))))) (PP (IN by) (NP (NP (JJ physiological) (NNS levels)) (PP (IN of) (NP (VBG circulating) (NN _PROT_))))) (PP (IN during) (NP (JJ normal) (NN feeding))))))
-1 #(S1 (S (NP (DT These) (NNS findings)) (VP (VBP are) (ADJP (JJ consistent) (PP (IN with) (NP (NP (VBN increased) (NN _PROT1_) (NN signaling)) (PP (TO to) (NP (NP (DT the) (NP (NN _PROT_)) (CC and) (NP (JJ POMC) (NNS neurons))) (PP (IN in) (NP (DT the) (NN ARC)))))))) (PP (IN by) (NP (NP (JJ physiological) (NNS levels)) (PP (IN of) (NP (VBG circulating) (NN _PROT2_))))) (PP (IN during) (NP (JJ normal) (NN feeding))))))
-1 #(S1 (S (NP (DT These) (NNS findings)) (VP (VBP are) (ADJP (JJ consistent) (PP (IN with) (NP (NP (VBN increased) (NN _PROT_) (NN signaling)) (PP (TO to) (NP (NP (DT the) (NP (NN _PROT1_)) (CC and) (NP (JJ POMC) (NNS neurons))) (PP (IN in) (NP (DT the) (NN ARC)))))))) (PP (IN by) (NP (NP (JJ physiological) (NNS levels)) (PP (IN of) (NP (VBG circulating) (NN _PROT2_))))) (PP (IN during) (NP (JJ normal) (NN feeding))))))
+1 #(S1 (S (NP (NN _PROT1_)) (ADVP (RB Rapidly)) (VP (VP (VBZ Inhibits) (NP (NP (JJ Hypothalamic) (NN _PROT2_) (NN _PROT2_)) (NN Secretion))) (CC and) (VP (VBZ Stimulates) (NP (NP (JJ Corticotropin-Releasing) (NN Hormone) (NN Secretion)) (PP (IN in) (NP (JJ Adrenalectomized) (NNS Mice))))))))
+1 #(S1 (S (NP (NN _PROT1_)) (VP (MD may) (ADVP (RB rapidly)) (VP (VBP inhibit) (NP (NN food) (NN intake)) (PP (IN by) (S (VP (VBG altering) (NP (NP (NP (DT the) (NN secretion)) (PP (IN of) (NP (NP (JJ hypothalamic) (NNS neuropeptides)) (PP (JJ such) (IN as) (NP (NP (NP (NN _PROT2_) (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (NN NPY)) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (NN stimulator)) (PP (IN of) (NP (NN food) (NN intake)))) (, ,) (CC and/or) (NP (NP (JJ corticotropin-releasing) (NN hormone)) (PRN (-LRB- -LRB-) (NP (NN CRH)) (-RRB- -RRB-)))))))) (, ,) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NN food) (NN intake))))))))))))
-1 #(S1 (S (NP (PRP We)) (VP (VBD measured) (NP (NP (NNS concentrations)) (PP (IN of) (NP (NP (NP (NP (NN _PROT1_)) (CC and) (NP (NP (NN CRH)) (PP (IN in) (NP (JJ specific) (JJ hypothalamic) (NNS regions))))) (NNS [i.e.)) (, ,) (NP (NP (NP (JJ arcuate) (NN nucleus)) (PRN (-LRB- -LRB-) (NP (NN ARC)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ paraventricular) (NN nucleus)) (PRN (-LRB- -LRB-) (NP (NN PVN)) (-RRB- -RRB-))) (, ,) (NP (JJ ventromedial) (NN nucleus)) (CC and) (NP (JJ dorsomedial) (NN nucleus))))) (-RRB- -RSB-) (PP (IN of) (NP (ADJP (CD 7-) (TO to) (JJ 8-wk-old)) (ADJP (ADJP (JJ lean)) (CC and) (ADJP (JJ ob/ob))) (NNS mice)))) (PP (IN at) (NP (QP (CD 1) (CC or) (CD 3)) (NN h))) (PP (IN after) (NP (JJ intracerebroventricular) (NN _PROT2_) (NN administration))))))
-1 #(S1 (S (NP (NP (DT No) (JJ rapid-onset) (NNS effects)) (PP (IN of) (NP (NN _PROT1_))) (PP (IN on) (NP (NP (JJ hypothalamic) (NN _PROT2_)) (CC or) (NP (NN CRH) (NNS concentrations))))) (VP (VBD were) (VP (VBN observed) (PP (IN in) (NP (JJ intact) (NNS mice)))))))
-1 #(S1 (S (NP (NP (DT The) (NN addition)) (PP (IN of) (NP (NN _PROT1_))) (PP (TO to) (NP (NP (JJ hypothalamic) (NNS preparations)) (PP (IN from) (NP (JJ intact) (NNS mice)))))) (ADVP (RB also)) (VP (VBD did) (RB not) (VP (VB alter) (NP (NP (NN _PROT2_)) (CC or) (NP (NN CRH) (NN secretion)))))))
+1 #(S1 (S (PP (IN Within) (NP (NP (CD 20) (NN min)) (PP (IN after) (NP (NP (NN exposure)) (PP (TO to) (NP (NN _PROT1_))))))) (, ,) (NP (NP (NN _PROT2_) (NN secretion)) (PP (IN from) (NP (NP (JJ hypothalamic) (NNS preparations)) (VP (VBN obtained) (PP (IN from) (NP (JJ adrenalectomized) (NNS mice))))))) (VP (VBD was) (VP (VBN lowered) (PP (IN by) (NP (NP (CD 27) (NN %)) (CC and) (NP (NN CRH) (NN secretion)))))) (VP (VBD was) (VP (VBN elevated) (PP (IN by) (NP (CD 51) (NN %)))))))
+1 #(S1 (S (NP (DT The) (JJ current) (NN study)) (VP (VBZ demonstrates) (SBAR (SBAR (IN that) (S (NP (NN _PROT1_)) (ADVP (RB rapidly)) (VP (VBZ influences) (NP (NP (DT the) (NN secretion)) (PP (IN of) (NP (NP (JJ hypothalamic) (NN _PROT2_)) (CC and) (NP (NN CRH)))))))) (CC and) (SBAR (IN that) (S (NP (NP (DT these) (NNS actions)) (PP (IN of) (NP (NN _PROT_))) (PP (IN within) (NP (DT the) (NN hypothalamus)))) (VP (VBP are) (VP (VBN restrained) (PP (IN by) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ endogenous) (NN corticosterone)))))))))))))
-1 #(S1 (S (NP (DT The) (JJ current) (NN study)) (VP (VBZ demonstrates) (SBAR (SBAR (IN that) (S (NP (NN _PROT1_)) (ADVP (RB rapidly)) (VP (VBZ influences) (NP (NP (DT the) (NN secretion)) (PP (IN of) (NP (NP (JJ hypothalamic) (NN _PROT_)) (CC and) (NP (NN CRH)))))))) (CC and) (SBAR (IN that) (S (NP (NP (DT these) (NNS actions)) (PP (IN of) (NP (NN _PROT2_))) (PP (IN within) (NP (DT the) (NN hypothalamus)))) (VP (VBP are) (VP (VBN restrained) (PP (IN by) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ endogenous) (NN corticosterone)))))))))))))
-1 #(S1 (S (NP (DT The) (JJ current) (NN study)) (VP (VBZ demonstrates) (SBAR (SBAR (IN that) (S (NP (NN _PROT_)) (ADVP (RB rapidly)) (VP (VBZ influences) (NP (NP (DT the) (NN secretion)) (PP (IN of) (NP (NP (JJ hypothalamic) (NN _PROT1_)) (CC and) (NP (NN CRH)))))))) (CC and) (SBAR (IN that) (S (NP (NP (DT these) (NNS actions)) (PP (IN of) (NP (NN _PROT2_))) (PP (IN within) (NP (DT the) (NN hypothalamus)))) (VP (VBP are) (VP (VBN restrained) (PP (IN by) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ endogenous) (NN corticosterone)))))))))))))
+1 #(S1 (S (NP (NP (JJ _PROT1_) (NN _PROT1_) (NN _PROT1_)) (PP (IN as) (NP (NP (DT a) (NN modulator)) (PP (IN of) (NP (NN _PROT2_) (NN _PROT2_) (NN _PROT2_))))))))
+1 #(S1 (S (PP (IN On) (DT the) (NN basis) (IN of) (NP (NP (JJ far-Western) (NN blot)) (CC and) (NP (NP (NP (NN plasmon) (NN resonance)) (PRN (-LRB- -LRB-) (NP (NN BIAcore)) (-RRB- -RRB-))) (NNS experiments)))) (, ,) (NP (PRP we)) (VP (VBP show) (ADVP (RB here)) (SBAR (IN that) (S (NP (NP (NP (JJ recombinant) (JJ _PROT1_) (NN _PROT1_) (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN bPrP)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NN 25-242)) (-RRB- -RRB-))) (ADVP (RB strongly)) (VP (VBZ interacts) (PP (IN with) (NP (NP (DT the) (JJ catalytic) (JJ alpha/alpha) (`` ') (NNS subunits)) (PP (IN of) (NP (NP (NN _PROT2_) (NN _PROT2_) (NN _PROT2_)) (PRN (-LRB- -LRB-) (ADVP (RB also)) (VP (VBN termed) (S (PRN (`` ') (NP (NN casein) (NN kinase) (CD 2)) ('' ')))) (-RRB- -RRB-))))))))))))
-1 #(S1 (S (NP (PRP We)) (ADVP (RB also)) (VP (VBP show) (SBAR (IN that) (S (NP (NN _PROT1_)) (VP (VBZ counteracts) (NP (NP (DT the) (NN inhibition)) (PP (IN of) (NP (NP (NN calmodulin) (NN phosphorylation)) (VP (VBN promoted) (PP (IN by) (NP (NP (DT the) (JJ regulatory) (NN beta) (NNS subunits)) (PP (IN of) (NP (NN _PROT2_)))))))))))))))
+1 #(S1 (S (NP (NP (DT A) (VBN truncated) (NN form)) (PP (IN of) (NP (NP (NN _PROT1_)) (VP (VBG encompassing) (NP (NP (DT the) (JJ C-terminal) (NN domain)) (PRN (-LRB- -LRB-) (NP (NNS residues) (NP (CD 105-242))) (-RRB- -RRB-))))))) (VP (VP (VBZ interacts) (PP (IN with) (NP (NN _PROT2_)))) (CC but) (VP (VBZ does) (RB not) (VP (VB affect) (NP (PRP$ its) (JJ catalytic) (NN activity)))))))
+1 #(S1 (S (NP (DT These) (NNS results)) (VP (VBP disclose) (NP (NP (DT the) (NN potential)) (PP (IN of) (NP (DT the) (NN _PROT1_))) (S (VP (TO to) (VP (VB modulate) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NP (NN _PROT2_)) (, ,) (NP (NP (DT a) (JJ pleiotropic) (NN _PROT_) (NN _PROT_)) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (ADJP (RB particularly) (JJ abundant) (PP (IN in) (NP (DT the) (NN brain))))))))))))))))))
-1 #(S1 (S (NP (DT These) (NNS results)) (VP (VBP disclose) (NP (NP (DT the) (NN potential)) (PP (IN of) (NP (DT the) (NN _PROT1_))) (S (VP (TO to) (VP (VB modulate) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NP (NN _PROT_)) (, ,) (NP (NP (DT a) (JJ pleiotropic) (NN _PROT2_) (NN _PROT2_)) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (ADJP (RB particularly) (JJ abundant) (PP (IN in) (NP (DT the) (NN brain))))))))))))))))))
-1 #(S1 (S (NP (DT These) (NNS results)) (VP (VBP disclose) (NP (NP (DT the) (NN potential)) (PP (IN of) (NP (DT the) (NN _PROT_))) (S (VP (TO to) (VP (VB modulate) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NP (NN _PROT1_)) (, ,) (NP (NP (DT a) (JJ pleiotropic) (NN _PROT2_) (NN _PROT2_)) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (ADJP (RB particularly) (JJ abundant) (PP (IN in) (NP (DT the) (NN brain))))))))))))))))))
